Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nitrofurantoin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Strides Pharma Science
Deal Size : Undisclosed
Deal Type : Acquisition
Strides Acquires Identified ANDAs from Nostrum Laboratories, USA
Details : The portfolio consists of liquids, including Nitrofurantoin, and immediate release solid orals to treat infections associated with UTIs, Pain Management, Allergy Symptoms, ADHD and Narcolepsy.
Product Name : Nitrofurantoin-Generic
Product Type : Antibiotic
Upfront Cash : Undisclosed
May 03, 2025
Lead Product(s) : Nitrofurantoin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Strides Pharma Science
Deal Size : Undisclosed
Deal Type : Acquisition